Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...
MIT-alumni-founded Thermedical advances novel deep-tissue ablation technology to address critical unmet needs in severe ventricular tachycardia ...
Cardiac Ablation Market by Trends, Dynamic Innovation in Technology Key Players and Forecast to 2030
Cardiac Ablation Market OverviewThe cardiac ablation market is set to grow at an impressive CAGR of approximately 13% over the forecast period, driven by a combination of clinical, technological, and ...
A recent study published in Pacing and Clinical Electrophysiology (PACE) determined that the use of catheter ablation to treat supraventricular tachycardia (SVT) is not detrimental to patients. This ...
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today ...
SAN FRANCISCO -- Noninvasive stereotactic radiotherapy (RT) for refractory ventricular tachycardia (VT) achieved outcomes similar to catheter ablation with substantially fewer serious adverse events ...
Intramural needle ablation using in-catheter, heated saline-enhanced radiofrequency was effective in reducing ventricular tachycardia burden for high-risk patients failing one to five prior ablations ...
Patients with structural heart disease are at risk for life-threatening ventricular tachycardias (VTs). Implantable cardioverter-defibrillators (ICDs) can terminate VT, but often at the cost of ...
Medical Device Network on MSN
Thermedical treats first patient in trial of SERF ablation system for VT
Thermedical has treated the first patient in a pivotal clinical trial of its saline-enhanced radiofrequency (SERF) ablation ...
Chloé Dygert has undergone surgery to treat supraventricular tachycardia (SVT), a condition which causes episodes where the heart beats much faster than usual. The North American rider revealed the ...
We demonstrated a significant rise in CRP at a median of 49 days after AF ablation. Although the subsequent decline in CRP observed at second follow-up (a median of 179 days after ablation) was not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback